These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20865667)

  • 21. Prognostic significance of BAF57 expression in patients with endometrial carcinoma.
    Kagami S; Kurita T; Kawagoe T; Toki N; Matsuura Y; Hachisuga T; Matsuyama A; Hashimoto H; Izumi H; Kohno K
    Histol Histopathol; 2012 May; 27(5):593-9. PubMed ID: 22419023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
    Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
    Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
    Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].
    Gottwald L; Kubiak R; Pasz-Walczak G; Sek P; Piekarski J; Szwalski J; Spych M; Chałubińska-Fendler J; Suzin J; Tyliński W; Jeziorski A
    Ginekol Pol; 2013 Feb; 84(2):95-101. PubMed ID: 23668054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STAT3 and apoptosis regulators: Bak and Bcl-xL in endometrioid adenocarcinomas of different estrogen receptor-α immunoprofile.
    Wincewicz A; Baltaziak M; Kanczuga-Koda L; Koda M; Sulkowska U; Famulski W; Sulkowski S
    Gynecol Endocrinol; 2011 Aug; 27(8):536-40. PubMed ID: 21726118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas.
    Zhang X; Dong Y; Ti H; Zhao J; Wang Y; Li T; Zhang B
    Hum Pathol; 2013 Nov; 44(11):2571-80. PubMed ID: 24071015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus.
    Ervine A; Leung S; Gilks CB; McCluggage WG
    Histopathology; 2014 May; 64(6):840-6. PubMed ID: 24267480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastasis-associated protein 3 in colorectal cancer determines tumor recurrence and prognosis.
    Huang Y; Li Y; He F; Wang S; Li Y; Ji G; Liu X; Zhao Q; Li J
    Oncotarget; 2017 Jun; 8(23):37164-37171. PubMed ID: 28418887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker.
    Hoshimoto K; Yamauchi N; Takazawa Y; Onda T; Taketani Y; Fukayama M
    Pathol Res Pract; 2003; 199(2):71-7. PubMed ID: 12747468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
    Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
    Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
    Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
    Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
    Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoexpression of PAX 8 in endometrial cancer: relation to high-grade carcinoma and p53.
    Brunner AH; Riss P; Heinze G; Meltzow E; Brustmann H
    Int J Gynecol Pathol; 2011 Nov; 30(6):569-75. PubMed ID: 21979593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.
    Ino K; Yoshida N; Kajiyama H; Shibata K; Yamamoto E; Kidokoro K; Takahashi N; Terauchi M; Nawa A; Nomura S; Nagasaka T; Takikawa O; Kikkawa F
    Br J Cancer; 2006 Dec; 95(11):1555-61. PubMed ID: 17117179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship between the expression of dual specificity phosphatase-1 and the prognosis of endometrioid adenocarcinoma].
    Gao BR; Yao YY; Chen YH; Li XP; Wang JL; Wei LH
    Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2493-5. PubMed ID: 24300273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
    Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.
    Hoang LN; Lee YS; Karnezis AN; Tessier-Cloutier B; Almandani N; Coatham M; Gilks CB; Soslow RA; Stewart CJ; Köbel M; Lee CH
    Histopathology; 2016 Oct; 69(4):560-9. PubMed ID: 27101785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L1CAM: amending the "low-risk" category in endometrial carcinoma.
    Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.